Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 11/20 | 1.00 |
| ▸ | OPRL1 | P41146 | 10/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 7/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6472981 | 0.86 | OPRM1 (0.79) | OPRM1OPRL1KCNH2SIGMAR1ALDH1A1 | |
| SCHEMBL6471078 | 0.86 | OPRL1 (1.00) | OPRM1OPRL1KCNH2SIGMAR1ALDH1A1 | |
| SCHEMBL6473181 | 0.86 | OPRM1 (1.00) | OPRM1OPRL1KCNH2SIGMAR1 | |
| SCHEMBL6501570 | 0.85 | OPRM1 (1.00) | OPRM1OPRL1KCNH2SIGMAR1ALDH1A1 | |
| SCHEMBL6471228 | 0.85 | OPRM1 (1.00) | OPRM1OPRL1KCNH2SIGMAR1ALDH1A1 | |
| SCHEMBL6504252 | 0.83 | OPRM1 (0.92) | OPRM1OPRL1KCNH2SIGMAR1ALDH1A1 | |
| SCHEMBL6471140 | 0.83 | OPRM1 (1.00) | OPRM1OPRL1KCNH2SIGMAR1ALDH1A1 | |
| SCHEMBL6504432 | 0.81 | KCNH2 (0.67) | OPRM1OPRL1KCNH2CYP2D6 | |
| SCHEMBL6506705 | 0.81 | KCNH2 (0.67) | OPRM1OPRL1KCNH2CYP2D6 | |
| SCHEMBL6504782 | 0.81 | OPRL1 (0.67) | OPRM1OPRL1KCNH2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | ITO FUMITAKA (JP) | 2005-07-14 | — | — | US | claimed |
| WO-2005016913-A1 | TETRAHYDROISOQUINOLINE OR ISOCHROMAN COMPOUNDS AS ORL-1 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN AND CNS DISORDERS | PFIZER JAPAN, INC. (JP) | 2005-02-24 | — | — | WO | claimed |
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | ITO FUMITAKA (JP) | 2005-07-14 | — | — | US | disclosed |
| WO-2005016913-A1 | TETRAHYDROISOQUINOLINE OR ISOCHROMAN COMPOUNDS AS ORL-1 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN AND CNS DISORDERS | PFIZER JAPAN, INC. (JP) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | OPRL1, NR1H3, HRH3 | OPRM1 8/4885OPRL1 1/4885KCNH2 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.